What is OTOF-related deafness?

OTOF mutations cause DFNB9, a congenital sensorineural hearing loss affecting 2-8% of cases. Otoferlin protein fails, blocking sound signals. 88

How does the AAV1-hOTOF gene therapy work?

AAV1 vector delivers functional OTOF gene to inner ear hair cells via injection, restoring otoferlin and auditory synapses. Effects start in weeks. 87

What were the trial results at Fudan University?

90% of 42 patients recovered hearing; ABR improved to ~50 dB; sustained 2.5 years, best in children. 88

Which Chinese universities led this research?

Fudan University Eye & ENT Hospital primary; Zhengzhou U, Central South U, Sichuan U collaborators.

Is the therapy safe long-term?

No serious AEs; well-tolerated up to 2.5 years. Minor neutropenia transient.

Who is Prof. Yilai Shu?

Lead at Fudan; pioneered OTOF therapy with Harvard ties. Key in China's gene editing labs.

What are implications for biotech careers in China?

Boosts PhD/postdoc roles in gene therapy at Fudan, etc. Rising funding for auditory genetics.

Will this therapy expand to other deafness genes?

Yes; platform for GJB2, TMC1. FDA approved similar; China fast-tracking.

Why better results in younger patients?

Higher cochlear plasticity; preserved hair cells. Adults had ~67% response.

How to access gene therapy research jobs in China?

Platforms like AcademicJobs list faculty/research roles at Fudan, Sichuan U in biotech.

What funding supported Fudan’s trial?

NSFC, National Key R&D, Shanghai commissions; exemplifies China’s higher ed investment.

Chinese Gene Therapy Restores Hearing 90% | Fudan Uni

a man looking at a man's head — Photo by OPPO Find X5 Pro on Unsplash

Chinese scientists have achieved a remarkable milestone in medical research with a gene therapy that restores hearing in 90% of patients suffering from a rare form of congenital deafness. This breakthrough, detailed in a landmark clinical trial, highlights the cutting-edge work at Fudan University and other leading Chinese institutions, positioning them at the forefront of global biotechnology innovation.

The therapy targets mutations in the OTOF gene, responsible for otoferlin protein deficiency, which disrupts sound transmission in the inner ear. Previously untreatable except through cochlear implants or hearing aids, this one-time treatment offers a potential cure, sparking excitement in academic circles for its implications on genetic medicine research programs across Chinese universities.

🔬 The Science of OTOF-Related Deafness

Autosomal recessive deafness 9 (DFNB9), caused by biallelic OTOF mutations, affects 2-8% of congenital hearing loss cases worldwide. Otoferlin, a protein in inner hair cells, is crucial for synaptic transmission of auditory signals to the brain. Without it, patients experience profound sensorineural hearing loss from birth.

In China, where genetic screening has identified thousands of such cases, universities like Fudan have prioritized hereditary hearing loss research. The OTOF protein's role was first elucidated in labs affiliated with Fudan University Eye & ENT Hospital, laying the groundwork for therapeutic interventions.

The Innovative Gene Therapy Approach

Researchers developed an adeno-associated virus serotype 1 (AAV1) vector carrying a functional human OTOF gene (AAV1-hOTOF). Delivered via intratympanic injection into the inner ear, it transduces hair cells to produce otoferlin, restoring auditory synapse function. This dual-AAV strategy ensures efficient delivery without surgical risks associated with cochlear implants.

The process involves precise dosing—ranging from 1.5 × 10¹² to higher viral genomes per ear—administered bilaterally in some cases. Improvements manifest within weeks, with auditory brainstem responses (ABR) thresholds dropping dramatically from over 97 dB to around 50 dB within a year.

Clinical Trial: Scale, Design, and Execution

Launched in 2022 and registered as ChiCTR2200063181, this single-arm, multicenter trial spanned eight Chinese sites, enrolling 42 patients aged 0.8 to 32.3 years. Led by Prof. Yilai Shu at Fudan University's Eye & ENT Hospital, with collaborators from Zhengzhou University, Central South University, Sichuan University, and others, it was the largest and longest such study.

39 children/teens (9 months-18 years) and 3 adults.
Three dose cohorts tested for safety and efficacy.
Primary endpoint: no dose-limiting toxicities (achieved).
Follow-up: up to 2.5 years, with ABR, audiometry, and speech assessments.

The trial's success underscores coordinated efforts among China's top medical universities.

Graph showing auditory brainstem response thresholds improving over 2.5 years in OTOF gene therapy trial participants

Impressive Results: 90% Hearing Recovery

Ninety percent of treated ears (38/42) demonstrated hearing recovery. ABR thresholds improved from profound loss (>97 dB nHL) to moderate levels (42-54 dB nHL) by 2.5 years. Behavioral audiometry shifted from >96 dB HL to 37 dB HL. Speech perception enhanced, with children developing language skills previously impossible.

Younger patients (<18 years) and those with preserved outer hair cell function (via DPOAE) or non-truncated mutations fared best—100% response in optimal subgroups. Bilateral treatment yielded superior outcomes. For details, see the full Nature publication.

Safety Profile and Long-Term Durability

The therapy proved safe: no serious adverse events, only transient grade 3 neutropenia in some. Anti-AAV1 antibodies rose but did not hinder efficacy. Effects persisted and even improved gradually up to 2.5 years, suggesting stable gene expression without decline.

This durability addresses key concerns in gene therapy, validating AAV1-hOTOF for clinical use.

Fudan University and Collaborative Academic Excellence

Fudan University's Eye & ENT Hospital, under Prof. Shu Yilai, spearheaded development, supported by Shanghai Key Lab for Gene Editing and state funding. Collaborations with Zhengzhou U, Central South U, and Sichuan U exemplify China's networked research ecosystem. International ties with Harvard's Mass Eye & Ear enhanced rigor.

This positions Fudan as a biotech hub, attracting talent and funding for auditory genetics.

Global Ripple Effects and Regulatory Milestones

The trial inspired FDA approval of Regeneron's Otarmeni (April 2026) for OTOF deafness, the first gene therapy for hearing loss. China's NMPA fast-tracks AAV1-hOTOF. Similar therapies target GJB2 mutations (most common genetic deafness).

Read Fudan's earlier trial announcement for origins.

Implications for Higher Education and Research Careers in China

This success boosts biotech programs at Chinese universities, drawing PhD/postdoc talent. Fudan exemplifies how state labs foster innovation, creating jobs in gene editing, virology, and clinical trials. With China's R&D surpassing the US, universities like Fudan offer robust career paths in regenerative medicine.

Increased funding for auditory research centers.
Interdisciplinary training in CRISPR/AAV tech.
Global collaborations enhance faculty mobility.

Challenges: Non-Responders and Broader Applications

Ten percent non-response linked to age, mutation type, or cochlear health. Future trials explore boosters or combination therapies. Expanding to other genes (e.g., TMC1) remains key.

Ethical screening and equitable access pose hurdles for scaling in China.

Expert Perspectives and Future Outlook

Prof. Shu Yilai: "A paradigm shift for genetic deafness." Zheng-Yi Chen (Harvard): Potential for 200+ deafness genes. Experts predict commercialization by 2028, transforming otology globally.

Chinese universities gear up for phase III trials and spin-offs.

Researchers at Fudan University Eye & ENT Hospital preparing AAV1-hOTOF gene therapy injection

Career Opportunities in China's Biotech Boom

This advances careers in higher ed biotech. Roles in gene therapy research abound at Fudan, Sichuan U. Explore faculty positions or postdocs via specialized platforms.